DAVID JULES DRUTZ
Medical Practice in Chapel Hill, NC

6462028, Oct 8, 2002

Nov 25, 1998

09/199912

William Pendergast - Durham NC
Sammy R. Shaver - Chapel Hill NC
David J. Drutz - Chapel Hill NC
Janet L. Rideout - Raleigh NC
Benjamin R. Yerxa - Raleigh NC

Inspire Pharmaceuticals, Inc. - Durham NC

C07H 1910

514 47, 514 48, 514 50

The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y and/or P2Y purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.

6673779, Jan 6, 2004

Jun 5, 2002

10/163804

Karla M. Jacobus - Cary NC
Benjamin R. Yerxa - Raleigh NC
William Pendergast - Durham NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Michael K. James - Raleigh NC
Monroe Jackson Stutts - Chapel Hill NC
Cara Geary - Cincinnati OH
Eduardo R. Lazarowski - Durham NC

Inspire Pharmaceuticals, Inc. - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 3170

514 51, 536 2621

The present invention is directed to a method of stimulating ciliary beat frequency to promote mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genito-urinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages of a patient. The method comprises administering uridine triphosphates, adenosine triphosphates, cytidine triphosphates, or dinucleoside tetraphosphates and the derivatives thereof to an affected body of a patient, to treat dysfunction of the mucociliary clearance system as a result of impaired ciliary movement in the patient.

6420347, Jul 16, 2002

Jul 17, 1998

09/101840

Karla M. Jacobus - Cary NC
Benjamin R. Yerxa - Raleigh NC
William Pendergast - Durham NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Michael K. James - Raleigh NC
Monroe Jackson Stutts - Chapel Hill NC
Cary Geary - Seattle WA
Edwardo R. Lazarowski - Chapel Hill NC

Inspire Pharmaceuticals, Inc. - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

A61K 3170

514 51, 514 48, 514 47

A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartageners syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal spray or nasal or eye drops), oral, inhaled by nebulization, topical, injected, suppository, intra-operative by instillation or application, or ex vivo direct application to spermatozoa.

5962432, Oct 5, 1999

Jul 3, 1996

8/675555

Karol La Croix - Cary NC
Christy Shaffer - Chapel Hill NC
Karla Jacobus - Cary NC
Janet Rideout - Raleigh NC
David Drutz - Chapel Hill NC

Inspire Pharmaceuticals, Inc. - Durham NC

A61K 3170

514 47

A novel formulation of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucous secretions of the human airways, middle/inner ears, or sinuses is disclosed. The composition comprises UTP and aqueous solution having a therapeutic concentration between 5 and 35 mg/mL, which has controlled tonicity within the range of 250 to 1000 mOsM, pH-adjusted, having pH between 7. 0 and 7. 5; and sterile. The pH-adjusted formulation is capable of long-term storage in the refrigerated state, with a shelf life of up to 30 months if kept refrigerated at 5. degree. C. The formulation is delivered therapeutically either in a nebulized form using any of several commercially available nebulizers (e. g. , jet, ultrasonic, etc. ), or in liquid form.

5968913, Oct 19, 1999

Dec 23, 1997

8/996740

Karol K. LaCroix - Holly Springs NC
Christy L. Shaffer - Chapel Hill NC
Karla M. Jacobus - Carey NC
Janet L. Rideout - Raleigh NC
David J. Drutz - Chapel Hill NC
Richard C. Evans - Carey NC
William Pendergast - Durham NC

Inspire Pharmaceuticals, Inc. - Durham NC

A61K 908, A61K 3170

514 47

Novel pharmaceutical compositions of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucous secretions of the human airways, middle/inner ears or sinuses are disclosed. Novel Formulation I comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg/mL, a controlled tonicity within the range of 250 to 100 mOsM, a pH between 7. 0 and 7. 5, and is sterile. The pH-adjusted composition is capable of long-term storage in the refrigerated state with a shelf life of up to 30 months. Formulation I may be delivered therapeutically either in a nebulized form or in a liquid form. Novel Formulation II comprises UTP in an aqueous solution or suspension having a therapeutic concentration approaching the limit of UTP's solubility at ambient temperature. This high concentration allows delivery of a therapeutic amount of UTP in very small volumes (50 to 100. mu. L) suitable for administration via portable hand-held devices such as metered dose inhalers.

2011010, May 5, 2011

Oct 29, 2010

12/916205

Hamid R. Hoveyda - Bruxelles, BE
Eric Marsault - Quebec, CA
Helmut Thomas - Quebec, CA
Graeme Fraser - Rixensart, BE
Sylvie Beaubien - Quebec, CA
Axel Mathieu - Quebec, CA
Julien Beignet - Quebec, CA
Marc-André Bonin - Quebec, CA
Serge Phoenix - Quebec, CA
David Drutz - Chapel Hill NC, US
Mark Peterson - Quebec, CA
Sophie Beauchemin - Quebec, CA
Martin Brassard - Quebec, CA
Martin Vezina - Quebec, CA

A61K 38/12, C07K 5/08, C07K 5/087, A61K 38/26, A61P 3/04, A61P 3/10, A61P 25/00, A61P 25/32, A61P 9/00, A61P 1/00, A61P 3/00, A61P 1/16, A61P 5/00, A61P 25/30

514 48, 530331, 514 211, 514 117, 514 69, 514 175, 514 177

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.

2005008, Apr 28, 2005

Aug 5, 2004

10/912448

Stephen Friedman - Chapel Hill NC, US
David Drutz - Chapel Hill NC, US

Syntherica Corporation - Durham NC

C12Q001/68, G01N033/53, C07K016/44

435007100, 530387300, 435006000

Methods and compositions for the modulation of an immune response are provided. Compositions comprise a bi-functional surrogate antibody molecule that interacts with a ligand of interest, wherein the bi-functional surrogate antibody further has attached thereto an immunomodulatory agent and/or a transporting agent. The compositions of the invention find use in a method for delivering an immunomodulatory agent to a ligand of interest. Further provided are methods for modulating an immune response in a subject against a ligand of interest. The method comprises administering a therapeutically effective amount of a bi-functional surrogate antibody of the invention. The methods of the invention also find use in improving the clinical outcome of a subject in need of a modulation in the immune response. Methods are further provided for the treatment or prevention of a variety of conditions and/or disorders including cancer, autoimmune diseases, allergies, prions, and various diseases or conditions of bacterial, parasitic, yeast or viral etiology.

7432252, Oct 7, 2008

Mar 20, 2000

09/531851

William Pendergast - Durham NC, US
Sammy Ray Shaver - Chapel Hill NC, US
David J. Drutz - Chapel Hill NC, US
Janet L. Rideout - Raleigh NC, US
Benjamin R. Yerxa - Raleigh NC, US

Inspire Pharmaceuticals, Inc. - Durham NC

A61K 31/70

514 51

The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Yand/or P2Ypurinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.

2008021, Sep 4, 2008

Mar 6, 2008

12/043845

William Pendergast - Durham NC, US
Sammy Ray Shaver - Chapel Hill NC, US
David J. Drutz - Chapel Hill NC, US
Janet L. Rideout - Fuquay-Varina NC, US
Benjamin R. Yerxa - Raleigh NC, US

Inspire Pharmaceuticals, Inc. - Durham NC

A61K 31/7076, A61P 15/02

514 47

The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Yand/or P2Ypurinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.

2008019, Aug 14, 2008

Feb 8, 2008

12/028611

Hamid Hoveyda - Quebec, CA
Graeme L. Fraser - Rixensart, BE
Kamel Benakli - Skippack PA, US
Sophie Beauchemin - Quebec, CA
Martin Brassard - Quebec, CA
David Drutz - Chapel Hill NC, US
Eric Marsault - Quebec, CA
Luc Ouellet - Quebec, CA
Mark L. Peterson - Sherbrooke, CA
Zhigang Wang - Quebec, CA

A61K 31/395, C07D 267/00, A61P 3/00, A61P 9/00, A61P 25/00, A61P 35/04, A61P 19/00, A61P 29/00, A61P 1/00, A61P 5/00, C07C 43/205

514450, 540455, 568584

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.